During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
A "sexualised" clothing advertisement from Jack Wills has been banned after being deemed inappropriate for young people.
Lawyers in the US are attempting to seize £190,000 in life insurance taken out by San Bernardino Syed Rizwan Farook.
An Australian-style points-based immigration system could be introduced if Britain votes to leave the EU, Brexit campaigners have revealed.